[go: up one dir, main page]

PE20252442A1 - Proteinas de fusion de rsv trimericas estabilizadas sin un dominio de trimerizacion heterologo - Google Patents

Proteinas de fusion de rsv trimericas estabilizadas sin un dominio de trimerizacion heterologo

Info

Publication number
PE20252442A1
PE20252442A1 PE2025001832A PE2025001832A PE20252442A1 PE 20252442 A1 PE20252442 A1 PE 20252442A1 PE 2025001832 A PE2025001832 A PE 2025001832A PE 2025001832 A PE2025001832 A PE 2025001832A PE 20252442 A1 PE20252442 A1 PE 20252442A1
Authority
PE
Peru
Prior art keywords
fusion proteins
trimerization domain
rsv fusion
heterologous trimerization
stabilized trimeric
Prior art date
Application number
PE2025001832A
Other languages
English (en)
Inventor
Johannes Petrus Maria Langedijk
Mark Johannes Gerardus Bakkers
Annemart Koornneef
Jaroslaw Juraszek
Original Assignee
Msd Int Business Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Msd Int Business Gmbh filed Critical Msd Int Business Gmbh
Publication of PE20252442A1 publication Critical patent/PE20252442A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invencion se refiere a una proteina F del virus respiratorio sincitial (VRS) o a un fragmento de este; a un acido nucleico que codifica dicha proteina; a un vector que contiene el acido nucleico; y a una celula hospedera que comprende dicho acido nucleico. Asimismo, la invencion se refiere a una composicion que comprende uno o mas de los elementos mencionados, la cual previene la infeccion y/o la replicacion del VRS.
PE2025001832A 2023-02-21 2024-02-20 Proteinas de fusion de rsv trimericas estabilizadas sin un dominio de trimerizacion heterologo PE20252442A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP23157769 2023-02-21
PCT/EP2024/054257 WO2024175579A1 (en) 2023-02-21 2024-02-20 Stabilized trimeric rsv fusion proteins without a heterologous trimerzation domain

Publications (1)

Publication Number Publication Date
PE20252442A1 true PE20252442A1 (es) 2025-10-20

Family

ID=85321076

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2025001832A PE20252442A1 (es) 2023-02-21 2024-02-20 Proteinas de fusion de rsv trimericas estabilizadas sin un dominio de trimerizacion heterologo

Country Status (12)

Country Link
EP (1) EP4669347A1 (es)
KR (1) KR20250152090A (es)
CN (1) CN121013729A (es)
AU (1) AU2024224721A1 (es)
CL (1) CL2025002485A1 (es)
CO (1) CO2025011268A2 (es)
CR (1) CR20250352A (es)
DO (1) DOP2025000206A (es)
IL (1) IL322806A (es)
MX (1) MX2025009833A (es)
PE (1) PE20252442A1 (es)
WO (1) WO2024175579A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120329390A (zh) * 2025-03-03 2025-07-18 中国医学科学院医学生物学研究所 基于异源三聚体基序的蛋白的改造及应用
CN120209098B (zh) * 2025-03-07 2025-12-09 复星安特金(成都)生物制药有限公司 Rsv f蛋白可溶片段、自源三聚体结构域及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
ES2918381T3 (es) * 2009-07-15 2022-07-15 Glaxosmithkline Biologicals Sa Composiciones de proteína F de VRS y métodos para producir las mismas
WO2014160463A1 (en) * 2013-03-13 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prefusion rsv f proteins and their use
EP3880243A1 (en) 2018-11-13 2021-09-22 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins

Also Published As

Publication number Publication date
EP4669347A1 (en) 2025-12-31
WO2024175579A1 (en) 2024-08-29
MX2025009833A (es) 2025-09-02
AU2024224721A1 (en) 2025-10-09
DOP2025000206A (es) 2025-09-30
CL2025002485A1 (es) 2025-11-14
KR20250152090A (ko) 2025-10-22
CN121013729A (zh) 2025-11-25
IL322806A (en) 2025-10-01
CR20250352A (es) 2025-10-07
CO2025011268A2 (es) 2025-09-08

Similar Documents

Publication Publication Date Title
PE20252442A1 (es) Proteinas de fusion de rsv trimericas estabilizadas sin un dominio de trimerizacion heterologo
EA033386B1 (ru) Рекомбинантные иммуногенные полипептиды стеблевого домена гемагглютинина вируса гриппа а и их применение
EA202191622A1 (ru) Стабилизированные растворимые f-белки rsv до слияния
PE20190433A1 (es) Vacuna contra vrs
AR108442A1 (es) Proteínas de fusión gdf15 y usos de estas
CL2018000740A1 (es) Vectores del factor viii del virus adeno-asociado, partículas víricas asociadas y formulaciones terapéuticas que los comprenden
EA202191355A1 (ru) Стабилизированные f-белки rsv до слияния
BR112017027448A2 (pt) vacina contra rsv
CL2024001716A1 (es) Anticuerpo aislado que se une a la proteína e del virus del dengue.
MX2022000222A (es) Vectores virales recombinantes que contienen la proteina menor del virus del sindrome reproductor y respiratorio porcino (prrsv) y sus metodos de elaboracion y uso.
MX384992B (es) Combinaciones inmunógenas.
MX2017004664A (es) Conjugados de farmacos de anticuerpos modificados mediante glicoingenieria.
BR112022006578A2 (pt) Polipeptídeos de fusão e de hemaglutinina do vírus da cinomose canina
PE20190110A1 (es) Proteinas f de prefusion del vrs estabilizadas
CO2019013220A2 (es) Virus oncolíticos y método
MX2019000743A (es) Variantes de serinproteasa y polinucleotidos que las codifican.
MX2019003156A (es) Combinaciones de vacunas novedosas contra el virus del zika y construcciones de anticuerpos de adn para usar contra el virus del zika.
PE20251395A1 (es) Proteinas de fusion de hmpv de prefusion estabilizadas
BR112020026620A8 (pt) Mutantes de hemaglutinina do vírus influenza
CO2017011431A2 (es) Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina
BR112022011422A2 (pt) Imunógenos para vírus da caxumba e do sarampo e seus usos
PE20252244A1 (es) Proteinas de fusion fc de il-12
CO2023017249A2 (es) Proteínas de fusión tnfsf-l y usos de las mismas
NO20085201L (no) Rekombinante novirhabdoviruser og deres anvendelse
BR112019010927A2 (pt) construções de vetor viral para expressão de adjuvantes genéticos que ativam as vias de cd40 e sting